Hazlett, Burt & Watson
DXCM icon

Hazlett, Burt & Watson’s DexCom DXCM Stock Holding History

Hazlett, Burt & Watson’s Portfolio DXCM Stock Details DXCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$9K Hold
100
– – ﹤0.01% 714
2026
Q2 		$7K Hold
100
– – ﹤0.01% 732
2026
Q1 		$6K Hold
100
– – ﹤0.01% 757
2025
Q4 		$7K Hold
100
– – ﹤0.01% 748
2025
Q3 		$7K Hold
100
– – ﹤0.01% 699
2025
Q2 		$9K Hold
100
– – ﹤0.01% 599
2025
Q1 		$7K Sell
100
-17
-15% -$1.39K ﹤0.01% 619
2024
Q4 		$9K Sell
117
-10
-8% -$740 ﹤0.01% 556
2024
Q3 		$9K Hold
127
– – ﹤0.01% 542
2024
Q2 		$14K Hold
127
– – 0.01% 486
2024
Q1 		$17K Hold
127
– – 0.01% 455
2023
Q4 		$15K Hold
127
– – 0.01% 450
2023
Q3 		$12K Buy
127
+10
+9% +$1.13K 0.01% 476
2023
Q2 		$15K Buy
117
+17
+17% +$2.06K 0.01% 438
2023
Q1 		$12K Hold
100
– – 0.01% 430
2022
Q4 		$11K Hold
100
– – 0.01% 446
2022
Q3 		$8K Hold
100
– – 0.01% 472
2022
Q2 		$7K Hold
100
– – 0.01% 479
2022
Q1 		$13K Buy
+100
New +$10.9K 0.01% 444

Other funds holding DXCM

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $234B AUM 43.58% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Hazlett, Burt & Watson's DXCM Position: Q3 2026 in Review

Hazlett, Burt & Watson held its DexCom (DXCM) position steady in Q3 2026 at 100 shares worth $9K. The position accounts for ﹤0.01% of the portfolio, ranked #714.

Hazlett, Burt & Watson first reported a position in DXCM in Q1 2022 and has held it in 19 quarters since. The position peaked at $17K in Q1 2024. 863 funds tracked by Wall St. Rank hold DXCM as of Q3 2026.

  • Hazlett, Burt & Watson held 100 shares of DexCom worth $9K as of Q3 2026.
  • Hazlett, Burt & Watson left its DexCom share count unchanged in Q3 2026.
  • DexCom made up ﹤0.01% of Hazlett, Burt & Watson's portfolio in Q3 2026, its #714 holding.
  • Hazlett, Burt & Watson first reported a position in DexCom in Q1 2022 and has held it in 19 quarters since.
  • Hazlett, Burt & Watson's DexCom position peaked at $17K in Q1 2024.
  • 863 funds tracked by Wall St. Rank held DexCom as of Q3 2026.

Based on Hazlett, Burt & Watson's 13F filing for Q3 2026, filed 4 Nov 2026.